In this week’s newsletter

✅ We actually don’t need to call aging a disease. ✅ Cryonics with the help of AI. ✅ Novartis extends partnership with BioAge. ✅ Two new longevity cities. ✅ Already meme of the year. ✅ Report on progress in 2024.

🤙🏼 Want to connect? Add me on LinkedIn. 🙏🏼 Not subscribed to the LEVITY podcast on Youtube yet? Do it here. 🎧 More of a listener? The LEVITY podcast is also available on Spotify, Apple Podcasts and other places.

How ”intrinsic capacity” could unlock the future of longevity medicine

If you need a longevity slogan you probably want something better than ”intrinsic capacity”. I’m pretty confident that Bryan Johnson won’t swap ”don’t die” for ”intrinsic capacity” anytime soon.

But if you really don’t want to die and are prepared to properly educate yourself on what’s needed for that (hint: it’s not whatever Bryan Johnson is selling) then you should pay attention to those two words. Intrinsic capacity.

Allow me to explain.

ARPA-H is the Advanced Research Projects Agency for Health, a US federal agency launched in 2022 with a $1.3 billion budget. It’s DARPA's healthcare-focused sibling. While DARPA brought us the internet and GPS (among many, many other things), ARPA-H aims to transform how we prevent and treat disease.

One of their newest programs, PROSPR (Proactive Solutions for Prolonging Resilience), might just change how we approach aging. Instead of getting lost in the energy zapping debate about whether aging is a disease, they're trying something cleverer.

This is where those two words - intrinsic capacity - could become a potential regulatory gateway for aging treatments.

Subscribe to LEVITY Premium to read the rest.